ClinicalTrials.gg

TargetBeta

JAK1

Janus kinase 1 · also JAK1A, JTK3, JAK1B · FERM domain containing

15 programs in company-led studies act on JAK1, from 12 companies: 9 in phase 3, 5 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
upadacitinibruleAbbViephase 46424 runningJAK2, JAK3, TYK2ChEMBL
ruxolitinibruleIncytephase 49518 runningJAK2, JAK3, TYK2ChEMBL
baricitinibruleEli Lillyphase 4598 runningJAK2NCIt
tofacitinibrulePfizerphase 4943 runningJAK2, JAK3, TYK2ChEMBL
filgotinib maleateruleEisaiphase 421 runningJAK2, JAK3, TYK2NCIt
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 3318 runningFLT3, JAK2, JAK3the studies' text
filgotinibruleLakefront Biotherapeutics NVphase 3464 runningJAK2, JAK3, TYK2NCIt
ivarmacitinibruleJiangsu HengRui Medicinephase 3254 running–NCIt
momelotinibruleGlaxoSmithKlinephase 3174 runningACVR1, JAK2NCIt
abrocitinibrulePfizerphase 3303 running–ChEMBL
FXS5626Fosun Pharmaphase 333 runningTYK2the company's pipeline
brepocitinibrulePfizerphase 3252 runningTYK2NCIt
delgocitinibruleLEO Pharmaphase 3212 runningJAK2, JAK3, TYK2ChEMBL
golidocitinibruleDizal Pharmaceuticalsphase 3102 running–NCIt
ABBV-7828AbbViephase 111 running–the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.